B02 – Advances in Prostate Health
Recent advancements in men’s health have changed the options for patient treatments in both prostate cancer and benign prostatic hyperplasia (BPH). Significant advancements in external beam radiation have improved patient outcomes, however radiation toxicity still remains between 10-25% post prostate cancer treatment. The SpaceOAR device has shown to dramatically reduce the amount of radiation to the surrounding organs, and reducing radiation toxicity. The SpaceOAR procedure can be performed in and office setting, allowing the patient to continue with radiation while reducing the exposure to healthy surrounding organs.
Similar advancements have been made in BPH treatment by improving the safety profile in a minimally invasive office based surgery. The Rezum System introduces a new platform technology that delivers stored thermal energy in the form of water vapor producing instantaneous cell death in targeted tissue. The procedure provides the opportunity to treat hyperplasia of the central zone as well as the median lobe. This allows for effective BPH treatment in an office setting with minimal recovery for the patient. Both these innovative technologies will be featured at CMSA by Boston Scientific Corporation.
1. Describe the prevalence of prostate disease, and the impact in men’s health
2. List patient options for treatment by disease state
3. Recognizing improvements and benefits of current treatments; and the impact to patient quality of life